Cipla Limited: peers
Cipla Limited beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.
Side by side#
Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.
| Measure | Cipla Limitedbase CIPLA.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Dr. Reddy's Laboratories Limited DRREDDY.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Zydus Lifesciences Limited ZYDUSLIFE.NS · 🇮🇳 IN Percentile in Healthcare Percentile in India | Laurus Labs Limited LAURUSLABS.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Aurobindo Pharma Limited AUROPHARMA.NS · 🇮🇳 IN Percentile in Healthcare Percentile in India | Lupin Limited LUPIN.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Glenmark Pharmaceuticals Limited GLENMARK.BO · 🇮🇳 IN Percentile in Healthcare Percentile in India | Torrent Pharmaceuticals Limited TORNTPHARM.NS · 🇮🇳 IN Percentile in Healthcare Percentile in India | Group median |
|---|---|---|---|---|---|---|---|---|---|
| Size | |||||||||
| Market cap (Better neither way: ranked highest first) | $12.3 BNov 20, 2026 · Market data5th of 8 | $12.5 BNov 20, 2026 · Market data4th of 8 | $12.9 BNov 20, 2026 · Market data3rd of 8 | $13.4 BNov 20, 2026 · Market data2nd of 8 | $11.2 BNov 20, 2026 · Market data6th of 8 | $9.9 BNov 20, 2026 · Market data7th of 8 | $8.1 BNov 20, 2026 · Market data8th of 8 | $19.2 BNov 20, 2026 · Market data1st of 8 | $12.4 B8 ranked |
| Revenue (Better neither way: ranked highest first) | —— | $3.9 BFY2024 · SEConly one with it | —— | —— | —— | —— | —— | —— | $3.9 B— |
| Net income (Higher is better) | —— | $669 MFY2024 · SEConly one with it | —— | —— | —— | —— | —— | —— | $669 M— |
| Employees (Better neither way: ranked highest first) | 23,000As on 2018 · Profile3rd of 8 | 24,795As on 2022 · Profile1st of 8 | 23,026As on 2022 · Profile2nd of 8 | 3,872As on 2020 · Profile8th of 8 | 15,690As on 2023 · Profile5th of 8 | 18,971As on 2022 · Profile4th of 8 | 10,667Permanent Employees count as on March 2020 · Profile7th of 8 | 13,573As on 2022 · Profile6th of 8 | 17,3318 ranked |
| Growth | |||||||||
| Revenue growth (Higher is better) | ———— | +14.2%FY2024 · SEConly one with it58th— | ———— | ———— | ———— | ———— | ———— | ———— | +14.2%— |
| Revenue growth, 3 years a year (Higher is better) | ———— | +10.2%FY2024 · SEConly one with it53rd— | ———— | ———— | ———— | ———— | ———— | ———— | +10.2%— |
| Earnings per share growth (Higher is better) | ———— | -0.6%FY2024 · SEConly one with it36th— | ———— | ———— | ———— | ———— | ———— | ———— | -0.6%— |
| Margins and returns | |||||||||
| Gross margin (Higher is better) | ———— | 58.5%FY2024 · SEConly one with it50th— | ———— | ———— | ———— | ———— | ———— | ———— | 58.5%— |
| Operating margin (Higher is better) | ———— | 22.1%FY2024 · SEConly one with it90th— | ———— | ———— | ———— | ———— | ———— | ———— | 22.1%— |
| Net margin (Higher is better) | ———— | 17.4%FY2024 · SEConly one with it88th— | ———— | ———— | ———— | ———— | ———— | ———— | 17.4%— |
| Free cash flow margin (Higher is better) | ———— | 5.8%FY2024 · SEConly one with it64th— | ———— | ———— | ———— | ———— | ———— | ———— | 5.8%— |
| Return on equity (Higher is better) | ———— | 18.4%FY2024 · SEConly one with it90th— | ———— | ———— | ———— | ———— | ———— | ———— | 18.4%— |
| Return on invested capital (Higher is better) | ———— | 17.7%FY2024 · SEConly one with it74th— | ———— | ———— | ———— | ———— | ———— | ———— | 17.7%— |
| Valuation | |||||||||
| P/E ratio (Better neither way: ranked highest first) | 29.4×price Nov 20, 2026 · Market data5th of 849th46th | 27.1×price Nov 20, 2026 · Market data6th of 846th43rd | 23.7×price Nov 20, 2026 · Market data7th of 840th36th | 139.4×price Nov 20, 2026 · Market data1st of 892nd94th | 29.5×price Nov 20, 2026 · Market data4th of 849th46th | 17.3×price Nov 20, 2026 · Market data8th of 827th25th | 54.8×price Nov 20, 2026 · Market data3rd of 875th73rd | 82.4×price Nov 20, 2026 · Market data2nd of 885th86th | 29.5×8 ranked |
| Price to sales (Better neither way: ranked highest first) | 4.1×price Nov 20, 2026 · Market data5th of 852nd55th | 3.5×price Nov 20, 2026 · Market data6th of 848th51st | 4.5×price Nov 20, 2026 · Market data3rd of 855th57th | 18.4×price Nov 20, 2026 · Market data1st of 882nd93rd | 3.1×price Nov 20, 2026 · Market data8th of 844th46th | 3.4×price Nov 20, 2026 · Market data7th of 847th49th | 4.5×price Nov 20, 2026 · Market data4th of 855th57th | 13.0×price Nov 20, 2026 · Market data2nd of 878th88th | 4.3×8 ranked |
| Price to book (Better neither way: ranked highest first) | 3.3×price Nov 20, 2026 · Market data6th of 854th39th | 3.0×price Nov 20, 2026 · Market data7th of 850th36th | 4.0×price Nov 20, 2026 · Market data5th of 861st46th | 22.8×price Nov 20, 2026 · Market data1st of 893rd95th | 2.7×price Nov 20, 2026 · Market data8th of 846th31st | 4.1×price Nov 20, 2026 · Market data4th of 861st47th | 7.1×price Nov 20, 2026 · Market data3rd of 877th69th | 10.1×price Nov 20, 2026 · Market data2nd of 884th82nd | 4.1×8 ranked |
| Free cash flow yield (Higher is better) | ———— | 1.8%price Nov 20, 2026 · Market dataonly one with it75th— | ———— | ———— | ———— | ———— | ———— | ———— | 1.8%— |
| Financial strength | |||||||||
| Debt to equity (Lower is better) | ———— | 0.0×FY2024 · SEConly one with it12th— | ———— | ———— | ———— | ———— | ———— | ———— | 0.0×— |
| Net debt to EBITDA (Lower is better) | ———— | -0.1×FY2024 · SEConly one with it25th— | ———— | ———— | ———— | ———— | ———— | ———— | -0.1×— |
| Interest cover (Higher is better) | ———— | 25.4×FY2024 · SEConly one with it96th— | ———— | ———— | ———— | ———— | ———— | ———— | 25.4×— |
| Piotroski F-score (Higher is better) | —— | 2 of 9FY2024 · SEConly one with it | —— | —— | —— | —— | —— | —— | 2.0 of 9— |
| Scorecard | |||||||||
| Scorecard (Higher is better) | —— | 24 of 30FY2024 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 80% passed— |
| Valuation checks (Higher is better) | —— | 3 of 6FY2024 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 50% passed— |
| Growth checks (Higher is better) | —— | 5 of 6FY2024 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 83% passed— |
| Profitability checks (Higher is better) | —— | 6 of 6FY2024 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 100% passed— |
| Financial health checks (Higher is better) | —— | 6 of 6FY2024 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 100% passed— |
| Shareholder returns checks (Higher is better) | —— | 4 of 6FY2024 · Scorecardonly one with it | —— | —— | —— | —— | —— | —— | 67% passed— |
| Dividends | |||||||||
| Dividend yield (Higher is better) | ———— | 0.6%FY2024 · SEConly one with it41st— | ———— | ———— | ———— | ———— | ———— | ———— | 0.6%— |
| Shareholder yield (Higher is better) | ———— | 0.8%FY2024 · SEConly one with it28th— | ———— | ———— | ———— | ———— | ———— | ———— | 0.8%— |
| Dividend payout (Better neither way: ranked highest first) | ———— | 11.8%FY2024 · SEConly one with it25th— | ———— | ———— | ———— | ———— | ———— | ———— | 11.8%— |
| Dividend per share (Better neither way: ranked highest first) | —— | $0.47FY2024 · SEConly one with it | —— | —— | —— | —— | —— | —— | $0.47— |
Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Cipla Limited: National Stock Exchange of India, daily market-cap file; Dr. Reddy's Laboratories Limited: National Stock Exchange of India, daily market-cap file; Zydus Lifesciences Limited: National Stock Exchange of India, daily market-cap file; Laurus Labs Limited: National Stock Exchange of India, daily market-cap file; Aurobindo Pharma Limited: National Stock Exchange of India, daily market-cap file; Lupin Limited: National Stock Exchange of India, daily market-cap file; Glenmark Pharmaceuticals Limited: National Stock Exchange of India, daily market-cap file; Torrent Pharmaceuticals Limited: National Stock Exchange of India, daily market-cap file.
Where each stands in its sector and country: Operating margin#
The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.
| Company | Operating margin | In its sector | In its country |
|---|---|---|---|
| Cipla Limited | — | — | — |
| Dr. Reddy's Laboratories Limited | 22.1%FY2024 | 90th percentile in Healthcaremedian -7.7%, 674 companies | — |
| Zydus Lifesciences Limited | — | — | — |
| Laurus Labs Limited | — | — | — |
| Aurobindo Pharma Limited | — | — | — |
| Lupin Limited | — | — | — |
| Glenmark Pharmaceuticals Limited | — | — | — |
| Torrent Pharmaceuticals Limited | — | — | — |
Revenue by fiscal year, and the rank in the group#
Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).
Revenue
Rank in the group
Ranks need two fiscal years with the figure for at least two of these companies.
| Fiscal year | Cipla Limited | Dr. Reddy's Laboratories Limited | Zydus Lifesciences Limited | Laurus Labs Limited | Aurobindo Pharma Limited | Lupin Limited | Glenmark Pharmaceuticals Limited | Torrent Pharmaceuticals Limited |
|---|---|---|---|---|---|---|---|---|
| 2024 | — | $3.9 BSEC | — | — | — | — | — | — |
| 2023 | — | $3.4 BSEC | — | — | — | — | — | — |
| 2022 | — | $3.1 BSEC | — | — | — | — | — | — |
| 2021 | — | $2.9 BSEC | — | — | — | — | — | — |
| 2020 | — | $2.6 BSEC | — | — | — | — | — | — |
| 2019 | — | $2.5 BSEC | — | — | — | — | — | — |
| 2018 | — | $2.2 BSEC | — | — | — | — | — | — |
| 2017 | — | $2.2 BSEC | — | — | — | — | — | — |
| 2016 | — | $2.1 BSEC | — | — | — | — | — | — |
| 2015 | — | $2.4 BSEC | — | — | — | — | — | — |
Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.
Suggested peers of Cipla Limited#
Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.
- Dr. Reddy's Laboratories LimitedDRREDDY.BO · 🇮🇳 IndiaSame industry: Pharmaceutical · Similar size: $12.5 B market cap against $12.3 B · Same country: India · Ratios of the last two fiscal years on fileMarket cap $12.5 B (Nov 20, 2026) · revenue $3.6 B (year to March 2026)100 of 100 (industry or sector 50 + size 30 + country 15 + figures on file 5)In the group
- Zydus Lifesciences LimitedZYDUSLIFE.NS · 🇮🇳 IndiaSame industry: Pharmaceutical · Similar size: $12.9 B market cap against $12.3 B · Same country: IndiaMarket cap $12.9 B (Nov 20, 2026) · revenue $2.9 B (year to March 2026)95 of 100 (industry or sector 50 + size 30 + country 15)In the group
- Laurus Labs LimitedLAURUSLABS.BO · 🇮🇳 IndiaSame industry: Pharmaceutical · Similar size: $13.4 B market cap against $12.3 B · Same country: IndiaMarket cap $13.4 B (Nov 20, 2026) · revenue $726 M (year to March 2026)94 of 100 (industry or sector 50 + size 30 + country 15)In the group
- Aurobindo Pharma LimitedAUROPHARMA.NS · 🇮🇳 IndiaSame industry: Pharmaceutical · Similar size: $11.2 B market cap against $12.3 B · Same country: IndiaMarket cap $11.2 B (Nov 20, 2026) · revenue $3.6 B (year to March 2026)94 of 100 (industry or sector 50 + size 29 + country 15)In the group
- Lupin LimitedLUPIN.BO · 🇮🇳 IndiaSame industry: Pharmaceutical · Similar size: $9.9 B market cap against $12.3 B · Same country: IndiaMarket cap $9.9 B (Nov 20, 2026) · revenue $3.0 B (year to March 2026)94 of 100 (industry or sector 50 + size 29 + country 15)In the group
- Glenmark Pharmaceuticals LimitedGLENMARK.BO · 🇮🇳 IndiaSame industry: Pharmaceutical · Similar size: $8.1 B market cap against $12.3 B · Same country: IndiaMarket cap $8.1 B (Nov 20, 2026) · revenue $1.8 B (year to March 2026)92 of 100 (industry or sector 50 + size 27 + country 15)In the group
- Torrent Pharmaceuticals LimitedTORNTPHARM.NS · 🇮🇳 IndiaSame industry: Pharmaceutical · Similar size: $19.2 B market cap against $12.3 B · Same country: IndiaMarket cap $19.2 B (Nov 20, 2026) · revenue $1.5 B (year to March 2026)92 of 100 (industry or sector 50 + size 27 + country 15)In the group
- Alkem Laboratories LimitedALKEM.NS · 🇮🇳 IndiaSame industry: Pharmaceutical · Similar size: $6.7 B market cap against $12.3 B · Same country: IndiaMarket cap $6.7 B (Nov 20, 2026) · revenue $1.6 B (year to March 2026)91 of 100 (industry or sector 50 + size 26 + country 15)+ Add
- Abbott India LimitedABBOTINDIA.BO · 🇮🇳 IndiaSame industry: Pharmaceutical · Similar size: $6.1 B market cap against $12.3 B · Same country: IndiaMarket cap $6.1 B (Nov 20, 2026) · revenue $748 M (year to March 2026)90 of 100 (industry or sector 50 + size 25 + country 15)+ Add
- Gland Pharma LimitedGLAND.NS · 🇮🇳 IndiaSame industry: Pharmaceutical · Similar size: $5.9 B market cap against $12.3 B · Same country: IndiaMarket cap $5.9 B (Nov 20, 2026) · revenue $691 M (year to March 2026)90 of 100 (industry or sector 50 + size 25 + country 15)+ Add
- Ipca Laboratories LimitedIPCALAB.BO · 🇮🇳 IndiaSame industry: Pharmaceutical · Similar size: $5.0 B market cap against $12.3 B · Same country: IndiaMarket cap $5.0 B (Nov 20, 2026) · revenue $1.0 B (year to March 2026)89 of 100 (industry or sector 50 + size 24 + country 15)+ Add
- GlaxoSmithKline Pharmaceuticals Limited (India)GLAXO.BO · 🇮🇳 IndiaSame industry: Pharmaceutical · Similar size: $5.0 B market cap against $12.3 B · Same country: IndiaMarket cap $5.0 B (Nov 20, 2026) · revenue $411 M (year to March 2026)89 of 100 (industry or sector 50 + size 24 + country 15)+ Add
Any figure over the years, other peers or a saved group: open this group in the peer workspace.